Pharma BD Deal Intelligence
GlaxoSmithKline strikes $300 million deal with 23andMe for genetics-driven drug research using consumer DNA database
Drug giant Glaxo teams up with DNA testing company 23andMe investing $300M for four-year drug discovery collaboration
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
GSK and 23andMe entered a four-year exclusive collaboration to leverage 23andMe's genetic database of 5+ million consented research participants to identify novel drug targets and develop new medicines. GSK invested $300M in 23andMe for an equity stake and the companies agreed to share development costs and revenues on jointly discovered programs. The collaboration aimed to use human genetics data to improve drug discovery success rates.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GlaxoSmithKline plc / 23andMe, Inc. (this deal) | 2018 | $300M | 37 |
| GlaxoSmithKline plc / Theravance, Inc. | 2012 | $213M | 82 |
| GlaxoSmithKline plc / Tesaro Inc. | 2018 | $5.1B | 79 |
| GlaxoSmithKline plc / Pfizer Inc. (Consumer Healthcare Division) | 2018 | $12.7B | 76 |
| GlaxoSmithKline plc / Novartis Consumer Healthcare JV | 2018 | $13.0B | 74 |
| GlaxoSmithKline plc / ID Biomedical Corporation | 2005 | $1.4B | 64 |
| GlaxoSmithKline plc / Vir Biotechnology Inc. | 2020 | $595M | 51 |
← Browse all deals · How we score deals
More: 2018 deals · GlaxoSmithKline plc deals · Immunology deals